Is transcatheter tricuspid valve-in-valve implantation a good option in patients with Ebstein anomaly?


eMediNexus    30 January 2018

A study published in the American Journal of Cardiology determined the acute results and short- to medium-term durability of transcatheter tricuspid valve-in-valve (TVIV) implantation within surgical bioprostheses among patients with Ebstein anomaly (EA). The investigators of this study revealed that transcatheter TVIV offers a low-risk, minimally invasive alternative to surgical tricuspid valve re-replacement in patients with EA and a failing tricuspid valve bioprosthesis. It was reported that TVIV was successful in the entire study cohort and there was no procedural mortality.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.